Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
|Articles|February 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 2
- Volume 4
- Issue 2
Cell Sorter Fails to Win Approval
ROCKVILLE, Md--The FDA has denied a request by CellPro, Inc. (Bothell, Wash) to approve its cell sorting device Ceprate SC, used investigationally to purify bone marrow or peripheral blood autografts by concentrating CD34+ stem cells. The FDA has asked the company to provide additional information on the device.
Advertisement
ROCKVILLE, Md--The FDA has denied a request by CellPro, Inc. (Bothell,Wash) to approve its cell sorting device Ceprate SC, used investigationallyto purify bone marrow or peripheral blood autografts by concentratingCD34+ stem cells. The FDA has asked the company to provide additionalinformation on the device.
Articles in this issue
almost 32 years ago
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packagesalmost 32 years ago
Multidisciplinary Approach Urged For Pain Reliefalmost 32 years ago
FDA Approves New Indication for Neupogen: Chronic Neutropeniaalmost 32 years ago
Department of Labor Wants to Study Possible Occupation-Cancer Linksalmost 32 years ago
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLCalmost 32 years ago
ASH Panel: How Many Hemotologists/Oncologists Are Enough?almost 32 years ago
Mammography Van Brings Breast Cancer Screening to the Workplacealmost 32 years ago
FDA to Build $600 Million Campusalmost 32 years ago
Finasteride Studied as Prostate Ca PreventiveAdvertisement
Related to this article
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5